Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Pharmacogenomics J. 2022 Apr 28;22(5-6):251–257. doi: 10.1038/s41397-022-00279-3

Figure 2. Frequency of rs4864950 AA, TA, and TT genotypes associated with (A) sorafenib-induced grade 2–3 composite toxicity in TARGET study, (B) sorafenib-induced grade 3 composite toxicity in CALGB 80802, and (C) regorafenib-induced grade 2–3 composite toxicity in the Italian cohort.

Figure 2.

The number above each bar represents the number of patients in each genotype.